Previous 10 | Next 10 |
Gainers: Dolphin Entertainment (DLPN) +163%.Benitec Biopharma (BNTC) +88%.Liquid Media (YVR) +51%.Takung Art (TKAT) +35%.Evolve Transition Infrastructure (SNMP) +27%.Genius Brands International (GNUS) +17%.The ONE Group Hospitality (STKS) +17%.Glory Star New Media (GSMG) +16%.Funko ...
Shares of Frequency Therapeutics (NASDAQ: FREQ) were crashing 74.9% as of 11:07 a.m. EDT on Tuesday. The huge drop came after the company announced disappointing top-line interim results from a phase 2a clinical study evaluating experimental therapy FX-322 in treating sensorineural ...
Gainers: Benitec Biopharma (BNTC) +71%, Hoth Therapeutics (HOTH) +26%, Aerpio Pharmaceuticals (ARPO) +12%, Soliton (SOLY) +11%, China Jo-Jo Drugstores (CJJD) +9%.Losers: Frequency Therapeutics (FREQ) -75%, Windtree Therapeutics (WINT) ...
Frequency Therapeutics (FREQ) slumps 73% premarket after announcing topline, day-90 data from its FX-322 Phase 2a study (FX-322-202).The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss ((SNHL)) did not demonstrat...
Frequency Therapeutics (FREQ) -71% after releases new data. from two FX-322 clinical studies; plans to advance single-dose regimen.Anixa Biosciences (ANIX) -23% after raises previously announced bought deal offering of common stock to $22.5M.Windtree Therapeutics (WIN...
Interim FX-322 Phase 2a Results Show Four Injection Schedule Had No Discernible Hearing Benefit Separate FX-322 Phase 1b Study Confirms Hearing Improvement from Single Injection Conference call at 8:30am ET today Frequency Therapeutics, Inc. (Nasdaq: FREQ), t...
Results Published in Leading Peer-Reviewed Otolaryngology Journal, Otology & Neurotology Statistically Significant Improvements Observed in Word Recognition Tests in Quiet and in Noise; Suggests Potential to Improve Speech Intelligibility, a Major Unmet Need for Individual...
On the heels of a phase 2a readout of the company's hearing loss treatment, JPMorgan analyst Anupam Rama upgrades shares of Frequency Therapeutics (FREQ) to Overweight. He lifts his price target to $56 from $27, suggesting about 50% upside from current levels.The final readout of da...
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Quentin McCubbin, Ph.D., as chief m...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
News, Short Squeeze, Breakout and More Instantly...
Frequency Therapeutics Inc. Company Name:
FREQ Stock Symbol:
NYSE Market:
Frequency Therapeutics, Inc. (Nasdaq: FREQ) today announced business updates and financial results for the second quarter ended June 30, 2023. In July, the Company announced that it entered into a definitive merger agreement with Korro Bio, Inc., a leading RNA editing company focused on the d...
2023-07-15 06:36:00 ET 3 Things to Know About Using Analyst Opinions for Trading Penny Stocks Trading penny stocks can be a thrilling venture, offering the potential for significant returns on small investments. One of the key aspects that can influence the success of such trades is the...
Merger to create a Nasdaq-listed genetic medicines company focused on advancing Korro Bio’s wholly owned portfolio of RNA editing programs Lead program is a disease modifying therapy for patients with alpha-1 antitrypsin deficiency (AATD), with preclinical data showing an increase ...